Valuation: Beta Bionics, Inc.

Market Cap 1.13B 1.01B 933M 846M 1.58B 107B 1.6B 11.19B 4.44B 56.06B 4.23B 4.14B 178B P/E 2026 *
-10.6x
P/E 2027 * -10.3x
Enterprise Value 979M 879M 812M 736M 1.38B 93.02B 1.39B 9.73B 3.86B 48.76B 3.68B 3.6B 155B EV / Sales 2026 *
7.87x
EV / Sales 2027 * 5.91x
Free-Float
99.19%
Yield 2026 *
-
Yield 2027 * -
1 day-16.78%
1 week-2.39%
Current month-5.37%
1 month-12.48%
3 months+13.67%
6 months+78.17%
Current year-41.06%
1 week 17.15
Extreme 17.1501
22.29
1 month 16.32
Extreme 16.32
22.29
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Sell

Executive/Senior Manager

-775 0.0014%
1/10/26 Sell

Executive/Senior Manager

-370 0.0007%
22/9/26 Sell

Director

-6,430 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-16.64%-2.39%-26.03% - 1.13B
+1.25%+1.05%+25.77%+61.55% 256B
+1.05%+0.23%+8.07%+26.63% 163B
+0.19%+4.34%-18.09%+72.81% 155B
-5.53%-5.28%-58.25%-15.76% 65.3B
+0.59%+3.40%+11.21%+46.58% 52.35B
+1.67%+1.85%-13.06%-7.19% 51.93B
+0.59%-1.40%+8.48%+66.10% 50.75B
+2.07%+1.86%+24.14%+78.97% 50.04B
+2.26%+4.38%+38.03%+101.74% 46.03B
Average -1.32%+3.62%+0.03%+47.94% 89.16B
Weighted average by Cap. +0.51%+1.71%+5.15%+49.86%

Financials

2026 *2027 *
Net sales 124M 112M 103M 93.46M 175M 11.81B 177M 1.24B 491M 6.19B 467M 457M 19.63B 183M 164M 151M 137M 257M 17.35B 260M 1.81B 721M 9.09B 686M 671M 28.84B
Net income -93.69M -84.09M -77.65M -70.41M -132M -8.9B -133M -931M -370M -4.66B -352M -344M -14.79B -103M -92.79M -85.68M -77.69M -145M -9.82B -147M -1.03B -408M -5.15B -388M -380M -16.32B
Net Debt -147M -132M -122M -110M -206M -13.94B -209M -1.46B -579M -7.31B -551M -539M -23.17B -46.25M -41.51M -38.33M -34.76M -64.97M -4.39B -65.76M -460M -183M -2.3B -174M -170M -7.3B
Projected Income Statement - Annual - Beta Bionics, Inc.
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
29/10/26 USD 17.93 -16.18% 959,953
27/10/26 USD 21.39 +4.29% 1,438,290
26/10/26 USD 20.51 +7.05% 1,630,975
23/10/26 USD 19.16 -0.93% 827,848
22/10/26 USD 19.34 +5.11% 685,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Beta Bionics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
21.39USD
Average target price
24.24USD
Spread / Average Target
+13.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Beta Bionics, Inc.
  1. Stock Market
  2. Stocks
  3. BBNX Stock